Explainer
Generic drugs and biosimilars: how copies of medicines are approved
A generic drug is an FDA-approved copy of a brand drug with the same active ingredient, strength, dosage form and route, shown to be bioequivalent rather than retested in full clinical trials.[1][2][3] Biologics are made from living sources and cannot be copied exactly, so their copies are biosimilars: highly similar products with no clinically meaningful differences.[4][5] FDA says most prescription drugs sold in the US are generics, and its biosimilar list ran from 2015 to October 2026.[6][7]
This page explains how copies of medicines are regulated in the US. It is general information, not medical or financial advice. Talk to your prescriber or pharmacist before switching between brand, generic or biosimilar versions of a medicine.
Generic drugs
FDA describes generic drugs as FDA-approved copies of brand drugs. They contain the same active ingredients, must work the same way in the body, and have the same strength, dosage form and route of administration.[1] The label is the same as the brand’s, with certain exceptions.[8] FDA says most prescription drugs sold in the US are generics, and that all approved drugs must meet the same quality standards wherever they are made.[6]
How a generic is approved
A generic company files an abbreviated new drug application (ANDA). It must show that its product is pharmaceutically equivalent and bioequivalent to the brand and can be made consistently, and approved generics are generally considered therapeutically equivalent.[9] Bioequivalence generally means the generic delivers the same amount of active ingredient at the same rate and to the same extent as the brand.[2] Generic makers do not repeat the brand’s animal and clinical studies; instead they show their product is therapeutically equivalent to the brand, which is one reason generics cost less.[3]
Same medicine, different look. FDA allows minor differences in appearance, such as colour.[10] It says differences in inactive ingredients usually do not matter clinically, but in a minority of patients they can affect tolerability or absorption. If a new version seems to work differently, raise it with your pharmacist or prescriber.[10]
Patents, exclusivity and the Orange Book. New brand drugs are usually protected by patents and marketing exclusivity. A generic that meets FDA standards can generally get final approval once these expire or the patents are successfully challenged.[11] FDA’s Orange Book lists approved drugs with their patent and exclusivity information. Not every prescription drug has a generic.[12]
Prices
FDA says a single generic competitor can cut prices by about 30%, and five competing generics are associated with price drops of nearly 85%. It cites an estimate that generics saved the US health system $2.2 trillion from 2009 to 2019.[13] FDA says ongoing drug shortages often persist partly because firms lack incentives to make older, less profitable products.[14]
Biosimilars
Biologics are made from natural and living sources and can consist of sugars, proteins, living cells or tissues. They are usually more complex than other drugs and often harder to purify and manufacture.[15] Because biologics vary slightly from batch to batch, they cannot be copied exactly.[4]
A biosimilar is a biologic that is highly similar to an FDA-approved reference product and has no clinically meaningful differences from it.[5] In NCI’s definition, it must be shown to be as safe as, work as well as and work in the same way as the reference drug.[5] FDA says biosimilars are used for conditions including psoriasis, chronic bowel diseases such as Crohn’s disease, diabetes, macular degeneration, arthritis, kidney conditions, multiple sclerosis, some cancers and osteoporosis, and that regulating insulin as a biologic allows multiple companies to make biosimilar insulins.[16]
Interchangeable biosimilars
An interchangeable biosimilar meets extra requirements so that a pharmacist may substitute it without consulting the prescriber, subject to state law.[17] In June 2024 FDA noted that 9 of the 13 interchangeable biosimilars approved by then had not needed switching studies, and proposed that such studies would generally not be needed.[18]
Exclusivity and the Purple Book
A reference biologic generally has a 12-year exclusivity period under the Public Health Service Act, and the expiry date marks when approval of a biosimilar referencing it may take effect. FDA’s Purple Book lists licensed biologics, including biosimilars and interchangeable products and their reference products.[19]
Approvals and recent policy
FDA’s list of approved biosimilars starts with Zarxio (filgrastim-sndz) in March 2015. The most recent entry on 7 November 2026 was Lucamzi (ranibizumab-blrz), approved in October 2026, and the table had 90 rows, some covering two brand names.[7] FDA says biosimilars may cost less because their makers rely on its earlier finding that the reference product is safe and effective, and that the lower price does not reflect lower safety or effectiveness.[20]
FDA has proposed reducing the testing it asks of biosimilar makers. In October 2025 it issued draft guidance on reducing comparative efficacy studies, which it says can take 1 to 3 years and cost $24 million. In March 2026 it issued draft guidance on streamlining pharmacokinetic testing.[21] FDA says drug pricing itself is outside its remit; government price-setting such as Medicare drug price negotiation runs separately.[22]
Read next
Drug shortages: why medicines run short and how they are tracked
Why US drug shortages happen, how FDA defines and tracks them, what manufacturers must report, what FDA can and cannot do, and the latest 2025 numbers.
Questions readers ask
Are generic drugs as good as brand-name drugs?
FDA says generics contain the same active ingredients, must work the same way in the body and must meet the same quality standards as brand drugs. Approved generics are generally considered therapeutically equivalent to the brand.[1][9][6]
Why does my generic pill look different?
FDA allows minor differences in appearance, such as colour. It says inactive ingredients usually make no clinical difference but can affect tolerability or absorption in a minority of patients.[10]
Why are generics cheaper?
Generic makers do not repeat the brand's clinical trials, and competition lowers prices. FDA says one generic competitor can cut prices by about 30% and five competitors are associated with drops of nearly 85%.[3][13]
What is the difference between a generic and a biosimilar?
A generic copies a conventional drug's active ingredient. A biosimilar is a copy of a biologic made from living sources, which cannot be copied exactly, so it must be highly similar with no clinically meaningful differences in safety and effectiveness.[1][4][5]
Can a pharmacist switch me to a biosimilar?
FDA says an interchangeable biosimilar, one that meets extra requirements, may be substituted without consulting the prescriber, subject to state law.[17]
Sources
· 22 claims from 2 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
FDA describes generic drugs as FDA-approved copies of brand drugs with the same active ingredients, strength, dosage form and route, which must work the same way in the body. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · What are generic drugs? (retrieved 2026-11-07)
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic drugs must meet the same high standards (retrieved 2026-11-07)
- [2]
Bioequivalence generally means the generic delivers the same amount of active ingredient at the same rate and to the same extent as the brand drug. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · What does bioequivalence mean? (retrieved 2026-11-07)
- [3]
Generic companies do not repeat the brand's clinical trials; they show therapeutic equivalence instead, which is one reason generics usually cost less. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · Why do generics often cost less? (retrieved 2026-11-07)
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic medicines cost less (retrieved 2026-11-07)
- [4]
Biosimilars are not identical to their reference products because biologics made from living sources normally vary slightly from batch to batch and cannot be copied exactly. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · FAQ, why aren't biosimilars identical? (retrieved 2026-11-07)
- NCI Dictionary of Cancer Terms: biosimilar drug · National Cancer Institute · Primary source · definition (retrieved 2026-11-07)
- [5]
A biosimilar is a biologic that is highly similar to an FDA-approved reference biologic and has no clinically meaningful differences from it in safety and effectiveness. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What is a biosimilar medication? (retrieved 2026-11-07)
- NCI Dictionary of Cancer Terms: biosimilar drug · National Cancer Institute · Primary source · definition (retrieved 2026-11-07)
- [6]
FDA says most prescription drugs sold in the US are generics, and all approved drugs must meet the same quality standards wherever they are made. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · Why does it seem like there are more problems with generic drugs? (retrieved 2026-11-07)
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · How does FDA ensure the quality of generic drugs manufactured outside of the U.S.? (retrieved 2026-11-07)
- [7]
FDA's list of approved biosimilars runs from Zarxio (filgrastim-sndz), approved in March 2015, to Lucamzi (ranibizumab-blrz), approved in October 2026, with 90 rows (some covering two brand names) when counted on 7 November 2026. confirmedas of 2026-11-07
- Biosimilar Product Information · US Food and Drug Administration · Primary source · FDA-Approved Biosimilar Products table, last row; row count by ContentLora (retrieved 2026-11-07)
- Biosimilar Product Information · US Food and Drug Administration · Primary source · FDA-Approved Biosimilar Products table, first row (retrieved 2026-11-07)
- [8]
A generic's label is the same as the brand-name label, with certain exceptions. confirmedas of 2026-11-07
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic drugs must meet the same high standards (retrieved 2026-11-07)
- [9]
Generic makers file an abbreviated new drug application (ANDA) showing the product is pharmaceutically equivalent and bioequivalent to the brand and can be made consistently; approved generics are generally considered therapeutically equivalent. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · What is the approval pathway for generic drugs? (retrieved 2026-11-07)
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · What is the approval pathway for generic drugs? (retrieved 2026-11-07)
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · What is the approval pathway for generic drugs? (retrieved 2026-11-07)
- [10]
FDA allows minor differences in appearance such as colour, and says differences in inactive ingredients usually do not matter clinically but can affect tolerability or absorption in a minority of patients. confirmedas of 2026-11-07
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · Why might a generic pill look different? (retrieved 2026-11-07)
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · Do differences in inactive ingredients matter clinically? (retrieved 2026-11-07)
- [11]
New brand drugs are usually protected by patents and marketing exclusivities; a generic that meets FDA standards can generally get final approval once these expire or the patents are successfully challenged. confirmedas of 2026-11-07
- Generic Drug Facts · US Food and Drug Administration · Primary source · Patents and exclusivities (retrieved 2026-11-07)
- Generic Drug Facts · US Food and Drug Administration · Primary source · Patents and exclusivities (retrieved 2026-11-07)
- [12]
FDA's Orange Book lists drugs approved on the basis of safety and effectiveness together with their patent and exclusivity information; not every prescription drug has a generic. confirmedas of 2026-11-07
- Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) · US Food and Drug Administration · Primary source · Orange Book page (retrieved 2026-11-07)
- Generic Drugs: Questions & Answers · US Food and Drug Administration · Primary source · Are all prescription drugs available as generics? (retrieved 2026-11-07)
- [13]
FDA says one generic competitor can cut prices by about 30% and five competing generics are associated with price drops of nearly 85%, and cites an estimate that generics saved the US health system $2.2 trillion from 2009 to 2019. confirmedas of 2026-11-07
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic medicines cost less (retrieved 2026-11-07)
- Generic Drug Facts · US Food and Drug Administration · Primary source · Generic medicines cost less (retrieved 2026-11-07)
- [14]
As of 31 December 2025 FDA had identified 93 ongoing shortages, a figure it presented as shortages yet to be resolved from previous years, and said shortages often persist because firms lack incentives to make older, less profitable products and manufacturing capacity is limited. confirmedas of 2026-11-07
- Report to Congress: Drug Shortages for Calendar Year 2025 · US Food and Drug Administration · Primary source · page 14 (PDF) (retrieved 2026-11-07)
- Report to Congress: Drug Shortages for Calendar Year 2025 · US Food and Drug Administration · Primary source · page 14 (PDF) (retrieved 2026-11-07)
- Report to Congress: Drug Shortages for Calendar Year 2025 · US Food and Drug Administration · Primary source · page 14 (PDF) (retrieved 2026-11-07)
- [15]
Biologics are made from natural and living sources and can consist of sugars, proteins, living cells or tissues; they are usually more complex than other drugs and often harder to purify and manufacture. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What are biologic medications? (retrieved 2026-11-07)
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What are biologic medications? (retrieved 2026-11-07)
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What are biologic medications? (retrieved 2026-11-07)
- [16]
FDA says biosimilars are used for conditions including chronic skin diseases such as psoriasis, chronic bowel diseases such as Crohn's disease, diabetes, macular degeneration, arthritis, kidney conditions, multiple sclerosis, some cancers and osteoporosis, and that regulating insulin as a biologic allows biosimilar insulins. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · Biosimilars are safe and effective (retrieved 2026-11-07)
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · Biosimilars are safe and effective (retrieved 2026-11-07)
- [17]
An interchangeable biosimilar meets extra requirements so that, depending on state law, a pharmacist may substitute it without consulting the prescriber. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What are interchangeable biosimilars? (retrieved 2026-11-07)
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · What are interchangeable biosimilars? (retrieved 2026-11-07)
- [18]
In June 2024 FDA noted that 9 of the 13 interchangeable biosimilars then approved had not needed switching-study data, and proposed that such studies generally would not be needed. confirmedas of 2026-11-07
- FDA updates guidance on interchangeability · US Food and Drug Administration · Primary source · statement dated 6/20/2024 (retrieved 2026-11-07)
- FDA updates guidance on interchangeability · US Food and Drug Administration · Primary source · statement dated 6/20/2024 (retrieved 2026-11-07)
- [19]
A reference biologic generally has a 12-year exclusivity period under the Public Health Service Act before a biosimilar referencing it can be approved, and the Purple Book records these dates. confirmedas of 2026-11-07
- Purple Book FAQs · US Food and Drug Administration · Primary source · FAQ Q2 (retrieved 2026-11-07)
- Purple Book FAQs · US Food and Drug Administration · Primary source · FAQ Q2 (retrieved 2026-11-07)
- Biosimilar Product Information · US Food and Drug Administration · Primary source · Learn More (retrieved 2026-11-07)
- [20]
Biosimilars may cost less because their makers rely on FDA's earlier finding that the reference product is safe and effective; FDA says the lower cost does not reflect lower safety or effectiveness. confirmedas of 2026-11-07
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · Lower costs (retrieved 2026-11-07)
- Biosimilars Basics for Patients · US Food and Drug Administration · Primary source · Lower costs (retrieved 2026-11-07)
- [21]
FDA issued draft guidance in October 2025 on reducing comparative efficacy studies for biosimilars, which it says can take 1 to 3 years and cost $24 million, and in March 2026 draft guidance on streamlining pharmacokinetic testing. confirmedas of 2026-11-07
- Biosimilars Action Plan · US Food and Drug Administration · Primary source · Goal 1 guidance list (retrieved 2026-11-07)
- FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable · US Food and Drug Administration · Primary source · press release, 9 March 2026 (retrieved 2026-11-07)
- FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable · US Food and Drug Administration · Primary source · press release, 9 March 2026 (retrieved 2026-11-07)
- [22]
FDA cannot require a company to keep making a drug it wants to discontinue, or to increase production, and drug pricing is outside FDA's remit. confirmedas of 2026-11-07
- Frequently Asked Questions about Drug Shortages · US Food and Drug Administration · Primary source · What is the major reason for drug shortages? (retrieved 2026-11-07)
- Frequently Asked Questions about Drug Shortages · US Food and Drug Administration · Primary source · What can FDA do to address drug shortages? (retrieved 2026-11-07)
- Frequently Asked Questions about Drug Shortages · US Food and Drug Administration · Primary source · Can FDA do anything about pricing of medications? (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: May 7, 2027.
Cite this page
"Generic drugs and biosimilars: how copies of medicines are approved." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/how-generic-drugs-and-biosimilars-work
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.